Studies show that BCL6 ( one of the markers we test for) can predict women with endometriosis and implantation failure.

Studies also show that women lacking the Beta-3 integrin have lower pregnancy rates than women who have the Beta-3 integrin.

BCL6 is dramatically over expressed in women with endometriosis, making BCL6 a likely candidate for the cause of progesterone resistance that contributes to implantation problems.

Although Beta-3 integrin can be normal in some women with endometriosis, BCL6 is an accurate predictor for the presence of inflammation, usually caused by endometriosis, adenomyosis or tubal disease.
Subscribe to our newsletter and stay up to date with ReceptivaDx.
The ReceptivaDxTM Test was developed by CiceroDx in conjunction with Pathology Consultants, Inc. of Greenville, SC. Pathology Consultants, Inc. is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). As with other laboratory-developed tests, this testing service has not been cleared or approved by the US FDA or any other federal regulatory agencies. Data have not been submitted to or evaluated by Federal regulatory agencies and the test is not for sale as an In Vitro Diagnostic (IVD) in the US or the EU.
© 2017 Receptivadx. All Rights Reserved